<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Bruker Corporation — News on 6ix</title>
    <link>https://6ix.com/company/bruker-corporation</link>
    <description>Latest news and press releases for Bruker Corporation on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 24 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/bruker-corporation" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354f7978dffbe2df0e6cb4.webp</url>
      <title>Bruker Corporation</title>
      <link>https://6ix.com/company/bruker-corporation</link>
    </image>
    <item>
      <title>Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-announces-date-and-time-of-first-quarter-2026-earnings-release-and-webcast</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-announces-date-and-time-of-first-quarter-2026-earnings-release-and-webcast</guid>
      <pubDate>Fri, 24 Apr 2026 11:00:00 GMT</pubDate>
      <description>BILLERICA, Mass., April 24, 2026--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends.</description>
    </item>
    <item>
      <title>Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-spatial-biology-showcases-high-fidelity-spatial-data-and-integrated-multi-platform-workflows-for-unprecedented-multiomic-insights-at-aacr-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-spatial-biology-showcases-high-fidelity-spatial-data-and-integrated-multi-platform-workflows-for-unprecedented-multiomic-insights-at-aacr-2026</guid>
      <pubDate>Fri, 17 Apr 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, April 17, 2026--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research.</description>
    </item>
    <item>
      <title>Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-expands-industry-leading-maldi-biotyperr-and-ir-biotyperr-workflows-for-microbial-identification-and-outbreak-management</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-expands-industry-leading-maldi-biotyperr-and-ir-biotyperr-workflows-for-microbial-identification-and-outbreak-management</guid>
      <pubDate>Fri, 17 Apr 2026 10:00:00 GMT</pubDate>
      <description>MUNICH, April 17, 2026--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges.</description>
    </item>
    <item>
      <title>Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-launches-mygenius-pror-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-launches-mygenius-pror-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026</guid>
      <pubDate>Fri, 17 Apr 2026 10:00:00 GMT</pubDate>
      <description>MUNICH, April 17, 2026--At ESCMID Global 2026, the Bruker Microbiology &amp; Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Li</description>
    </item>
    <item>
      <title>Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-unveils-new-nmr-products-and-workflow-solutions-at-enc-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-unveils-new-nmr-products-and-workflow-solutions-at-enc-2026</guid>
      <pubDate>Mon, 13 Apr 2026 11:00:00 GMT</pubDate>
      <description>ASILOMAR, Calif., April 13, 2026--At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (Nasdaq: BRKR) today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR. The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and dissolution Dynamic Nuclear Polarization (DNP), and digital workflows that support reproducible, unattended, and data</description>
    </item>
    <item>
      <title>Bruker Invests in Photothermal AFM-IR to Advance Semiconductor Research</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-invests-in-photothermal-afm-ir-to-advance-semiconductor-research</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-invests-in-photothermal-afm-ir-to-advance-semiconductor-research</guid>
      <pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
      <description>Dimension IconIR to Support Critical Materials Characterization for Next-Generation Semiconductor Devices BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker</description>
    </item>
    <item>
      <title>Bruker Announces Appointment of Thierry Bernard to its Board of Directors</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-announces-appointment-of-thierry-bernard-to-its-board-of-directors-2</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-announces-appointment-of-thierry-bernard-to-its-board-of-directors-2</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors,</description>
    </item>
    <item>
      <title>PreOmics GmbH and Biognosys AG Prevail in U.S. Patent Challenge</title>
      <link>https://6ix.com/company/bruker-corporation/news/preomics-gmbh-and-biognosys-ag-prevail-in-us-patent-challenge-2</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/preomics-gmbh-and-biognosys-ag-prevail-in-us-patent-challenge-2</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>US PTAB Revokes Sole Independent and Other Central Claims of U.S. Patent 11,435,360 SCHLIEREN, Switzerland &amp; MUNICH--(BUSINESS WIRE)-- PreOmics GmbH and</description>
    </item>
    <item>
      <title>Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-accelerates-the-future-of-diagnostic-and-prognostic-spatial-proteomics-with-the-launch-of-cellscape-xr</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-accelerates-the-future-of-diagnostic-and-prognostic-spatial-proteomics-with-the-launch-of-cellscape-xr</guid>
      <pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
      <description>The new platform delivers unmatched quantitation, robustness, and throughput to support clinical translation of spatial proteomics assays ORLANDO,</description>
    </item>
    <item>
      <title>Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-expands-collaboration-with-noetik-to-advance-tissue-foundational-models-for-translational-and-therapeutic-applications</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-expands-collaboration-with-noetik-to-advance-tissue-foundational-models-for-translational-and-therapeutic-applications</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>ORLANDO, Fla.--(BUSINESS WIRE)-- Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its</description>
    </item>
    <item>
      <title>Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-announces-major-advancements-at-agbt-to-enable-complete-high-fidelity-spatial-biology-across-the-biological-spectrum</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-announces-major-advancements-at-agbt-to-enable-complete-high-fidelity-spatial-biology-across-the-biological-spectrum</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>Portfolio innovations include the launch of the new CellScape XR spatial proteomics platform, the unique CosMx mouse whole transcriptome panel, the launch of</description>
    </item>
    <item>
      <title>Bruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-advances-functional-proteomics-20-with-timsomnitm-mass-spectrometry-proteoform-analysis-for-deeper-insights-into-disease-biology</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-advances-functional-proteomics-20-with-timsomnitm-mass-spectrometry-proteoform-analysis-for-deeper-insights-into-disease-biology</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>Novel timsOmni™ workflows enable deeper functional characterization of proteoforms and PTMs, leveraging multi-stage, ultra-sensitive trapped eXd molecular</description>
    </item>
    <item>
      <title>Bruker Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 12 Feb 2026 05:00:00 GMT</pubDate>
      <description>Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS</description>
    </item>
    <item>
      <title>Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-introduces-intapharmatm-a-labelfree-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-introduces-intapharmatm-a-labelfree-platform-for-nanoparticle-characterization-in-mrna-drug-and-gene-therapy-development-and-qc</guid>
      <pubDate>Mon, 09 Feb 2026 05:00:00 GMT</pubDate>
      <description>New iNTApharma system enables rapid, native‑state size and concentration measurements with single‑particle sensitivity for viral, vesicle, and nanoscale</description>
    </item>
    <item>
      <title>Bruker Announces Quarterly Preferred Stock Dividend</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-announces-quarterly-preferred-stock-dividend</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-announces-quarterly-preferred-stock-dividend</guid>
      <pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
      <description>BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a</description>
    </item>
    <item>
      <title>Bruker Announces Date and Time of Fourth Quarter 2025 Earnings Release and Webcast</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-announces-date-and-time-fourth-quarter-2025-earnings-release-and-webcast-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-announces-date-and-time-fourth-quarter-2025-earnings-release-and-webcast-2026</guid>
      <pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
      <description>BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2025 financial results</description>
    </item>
    <item>
      <title>Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board</title>
      <link>https://6ix.com/company/bruker-corporation/news/arch-biopartners-announces-appointment-of-dr-patrick-vink-as-chairman-of-the-board</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/arch-biopartners-announces-appointment-of-dr-patrick-vink-as-chairman-of-the-board</guid>
      <pubDate>Fri, 16 Jan 2026 13:15:00 GMT</pubDate>
      <description>TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15, 2026. Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported sev</description>
    </item>
    <item>
      <title>Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-announces-500-million-multi-year-orders-two-global-healthcare-companies-supply</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-announces-500-million-multi-year-orders-two-global-healthcare-companies-supply</guid>
      <pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
      <description>HANAU, Germany--(BUSINESS WIRE)-- The Bruker Energy &amp; Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced</description>
    </item>
    <item>
      <title>Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-consolidates-ownership-tofwerk-expansion-mass-spectrometry-portfolio-new</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-consolidates-ownership-tofwerk-expansion-mass-spectrometry-portfolio-new</guid>
      <pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
      <description>TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring,</description>
    </item>
    <item>
      <title>Bruker Corporation to Present at the J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/bruker-corporation/news/bruker-corporation-present-j-p-210100273</link>
      <guid isPermaLink="true">https://6ix.com/company/bruker-corporation/news/bruker-corporation-present-j-p-210100273</guid>
      <pubDate>Wed, 07 Jan 2026 21:01:00 GMT</pubDate>
      <description>BILLERICA, Mass., January 07, 2026--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time.</description>
    </item>
  </channel>
</rss>